GlobalData on MSN

MRM Health receives FDA clearance for STARFISH-UC Phase IIb trial

MRM Health has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) ...
Business Wire

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) ...
Agence France-Presse

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug ...
Medscape

Mild Crohn's Disease Has Worse Prognosis Than Mild Ulcerative Colitis

A new cohort study from Northern Denmark finds that mild-onset Crohn's disease (CD) has worse 10-year probability of progression to moderate-severe disease, at 53%, than that of mild-onset ulcerative ...

MRM Health NV: MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...